Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials.
Chen GL, Qiu YZ, Wu KQ, Wu Y, Wang YH, Zou YY, Peng CG, Zhao J, Su C, Ma JH, Ni SN, Wang X, Jin TH, Jiang Q, Guo T, Xu Y, Huang CC, Zhang Q, Liu KL, Ji L, Yang HY, Li CL, Su YW, Lu X, Li LJ.
Chen GL, et al. Among authors: zou yy.
Hum Vaccin Immunother. 2023 Dec 15;19(3):2285089. doi: 10.1080/21645515.2023.2285089. Epub 2023 Dec 18.
Hum Vaccin Immunother. 2023.
PMID: 38111106
Free PMC article.
Clinical Trial.